European registry of consecutive patients undergoing PCI [percutaneous coronary interventions] evaluating the use of the thrombin-specific anticoagulant bivalirudin with focus on patient selection, convenience and safety aspects.
Phase of Trial: Phase IV
Latest Information Update: 11 Aug 2013
At a glance
- Drugs Bivalirudin (Primary)
- Indications Thrombosis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Takeda Pharmaceuticals International GmbH
- 04 May 2012 Additional locations added as reported by ClinicalTrials.gov.
- 04 May 2012 Company added in the association field as reported by ClinicalTrials.gov.
- 12 Feb 2009 Actual end date (Sep 2007) added as reported by ClinicalTrials.gov.